Search results for "Diabetes mellitus."

showing 10 items of 2067 documents

No effect of oral insulin on residual beta-cell function in recent-onset Type I diabetes (the IMDIAB VII)

2000

Aims/hypothesis. Induction of tolerance to insulin is achievable in animal models of Type I (insulin-dependent) Diabetes mellitus by oral treatment with this hormone, which can lead to prevention of the disease. In the Diabetes Prevention Trial of Type I diabetes (DPT-1), oral insulin is given with the aim of preventing disease insurgence. We investigated whether if given at diagnosis of Type I diabetes in humans, oral insulin can still act as a tolerogen and therefore preserve residual beta-cell function, which is known to be substantial at diagnosis. Methods. A double-blind trial was carried out in patients (mean age ± SD: 14 ± 8 years) with recent-onset Type I diabetes to whom oral insul…

medicine.medical_specialtybusiness.industryC-peptideEndocrinology Diabetes and MetabolismInsulinmedicine.medical_treatmentPlacebomedicine.diseaseGastroenterologychemistry.chemical_compoundEndocrinologychemistryBasal (medicine)Oral administrationInternal medicineDiabetes mellitusInternal MedicinemedicinebusinessPancreatic hormoneHormoneDiabetologia
researchProduct

Relationship between Diabetes and Ischemic Stroke: Analysis of Diabetes- Related Risk Factors for Stroke and of Specific Patterns of Stroke Associate…

2015

Diabetes and ischemic stroke are common diseases that frequently occurring together. Among patients with diabetes mellitus several factors contribute in varying degrees to the overall cerebrovascular risk including hyperglycemia, vascular risk factors such as hypertension and dyslipidemia and also genetic, demographic, and lifestyle factors and several studies have shown that people with diabetes have approximately twice the risk of ischemic stroke compared with those without diabetes. The association between ischemic stroke and diabetes is bidirectional and it is not limited to acute ischemic stroke since diabetes may contribute to a more insidious brain damage represented by lacunar infar…

medicine.medical_specialtybusiness.industryCerebrovascular diseasesBrain damageDiabetemedicine.diseaseOmicsSurgeryStrokeDiabetes mellitusInternal medicineIschemic strokemedicineDementiacardiovascular diseasesRisk factormedicine.symptombusinessStrokeDyslipidemiaJournal of Diabetes & Metabolism
researchProduct

The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study

2020

Abstract Background Cardiovascular disease (CVD) is currently one of the leading cause of mortality in the European Union. Well-established, modifiable cardiovascular (CV) risk factors include hypertension (HTN), hypercholesterolaemia, diabetes mellitus (DM), obesity, low activity levels, poor diet and smoking. There are no current estimates on the prevalence of CV risk factors among Polish patients solely in the primary care setting. Methods A nationwide cross-sectional study, LIPIDOGRAM2015, was carried out in Poland in the 4th quarter of 2015 and 1st and 2nd quarters of 2016. 438 primary care physicians enrolled 13,724 adult patients that sought medical care for any medical reason in pri…

medicine.medical_specialtybusiness.industryCholesterolDiseaseOverweightmedicine.diseaseObesitychemistry.chemical_compoundBlood pressurechemistryDiabetes mellitusInternal medicineEpidemiologymedicinemedia_common.cataloged_instancemedicine.symptomEuropean unionCardiology and Cardiovascular Medicinebusinessmedia_commonEuropean Heart Journal
researchProduct

Spanish consensus on the physical health of patients with depressive disorders

2014

Comorbidity between depression and physical illnesses is very common and has a significant impact on the health and management of the patient. With the support of the Sociedades Espanolas de Psiquiatria y Psiquiatria Biologica, and Sociedad Espanola de Medicos de Atencion Primaria (SEMERGEN) a consensus was prepared on physical health in patients with depression and is summarized in the present work. The literature review highlighted the high frequency of cardiovascular and endocrine-metabolic disorders in patients with depression such as diabetes and obesity, thus making the primary and secondary prevention recommendations for patients with cardiovascular or metabolic risk applicable to pa…

medicine.medical_specialtybusiness.industryChronic painPrimary care physicianPhysical healthGeneral Medicinemedicine.diseaseObesityComorbidityTherapeutic approachDiabetes mellitusmedicinePsychiatrybusinessDepression (differential diagnoses)Revista de Psiquiatría y Salud Mental (English Edition)
researchProduct

[PTCA or bypass-surgery in patients with renal failure and diabetes - pro surgery].

2002

medicine.medical_specialtybusiness.industryCoronary DiseaseGeneral Medicinemedicine.diseasePrognosisSurgeryText miningBypass surgeryDiabetes mellitusmedicineHumansIn patientDiabetic NephropathiesAngioplasty Balloon CoronaryCoronary Artery BypassbusinessDiabetic AngiopathiesDeutsche medizinische Wochenschrift (1946)
researchProduct

2214Prevalence and severity of coronary disease in patients with familial hypercholesterolemia hospitalized for an acute myocardial infarction: data …

2019

Abstract Aim Individuals with heterozygous familial hypercholesterolemia (FH) are at high risk of early myocardial infarction (MI). However, coronary artery disease (CAD) burden of FH remains not well described. From a large database of a regional registry of acute MI, we aimed to address prevalence of FH and severity of CAD. Methods Consecutive patients hospitalized with MI in a multicentre database from 2001–2017 were considered. An algorithm, adapted from Dutch Lipid Clinic Network criteria, was built upon 4 variables (LDL-cholesterol (LDL-C) and lipid lowering agents, premature and family history of CAD) to identify FH probabilities. Results Among the 11624 patients included in the surv…

medicine.medical_specialtybusiness.industryCoronary arteriosclerosisFamilial hypercholesterolemiaCoronary diseasemedicine.diseaseEzetimibeInternal medicineDiabetes mellitusEpidemiologymedicineIn patientMyocardial infarctionCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal
researchProduct

Free Radicals and Antioxidants in Physical Exercise

1998

The beneficial effects of exercise are well documented. Indeed, it ameliorates diabetes mellitus, improves the plasma lipid profile, increases bone density and may help to lose weight. However, as stated in the old medical saying “the beneficial effects of exercise are lost with exhaustion”. It has been known for some time that exhaustive exercise causes muscle soreness, induces an elevation of cytosolic enzyme activities in blood plasma and may be harmful. In the last decade a considerable amount of information concerning production of free radicals in exhaustive exercise has been obtained. An international symposium took place in Valencia, Spain in 1993 and a book was published on the sub…

medicine.medical_specialtybusiness.industryDiabetes mellitusPlasma lipidsPhysical therapyMedicinePhysical exercisebusinessmedicine.diseaseBeneficial effects
researchProduct

Importancia de la dislipidemia en la enfermedad cardiovascular: un punto de vista

2015

The authors present their view on the prevention of cardiovascular diseases, accepting the European ESC/EAS guidelines. They consider that the aim of the lipid control, based on LDL-C goals, is essential for the prevention and treatment of cardiovascular diseases. In subjects with metabolic syndrome (mainly, abdominal obesity, pre-diabetes and diabetes), the primary objective should be apoB or Non-HDL-C, which are better associated with cardiovascular risk. The treatment must be lifestyle changes and control of other risk factors. After calculating cardiovascular risk, statins are the first therapeutic step, with the strength and dose needed to achieve LDL-C goals. If targets are not achiev…

medicine.medical_specialtybusiness.industryDiseaseArteriosclerosismedicine.diseaseEzetimibeAge groupsDiabetes mellitusInternal medicinemedicinelipids (amino acids peptides and proteins)Pharmacology (medical)Lipid controlmedicine.symptomMetabolic syndromeCardiology and Cardiovascular MedicinebusinessAbdominal obesitymedicine.drugClínica e Investigación en Arteriosclerosis
researchProduct

Daptomycin-induced eosinophilic pneumonia: Are there any risk factors?

2020

Abstract Objectives Daptomycin is a widely used antibiotic. Rhabdomyolysis related to daptomycin is one of the adverse effects of treatment, justifying the need for regular monitoring of muscle enzymes throughout treatment. Daptomycin may also lead to eosinophilic pneumonia. However, risk factors for this adverse reaction have not been identified and do not permit targeting of at-risk populations who could benefit from appropriate monitoring. Patients and methods Literature was reviewed for cases of daptomycin-induced eosinophilic pneumonia (DIEP), which that were compared to cases of patients without this adverse effect. Results Fifty patients with DIEP and 54 controls were identified. Age…

medicine.medical_specialtybusiness.industryDiseasemedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesDaptomycinRisk FactorsInternal medicineDiabetes mellitusmedicineEosinophilic pneumoniaHumansDaptomycinRisk factorPulmonary EosinophiliaAdverse effectbusinessRhabdomyolysisPulmonary EosinophiliaLungmedicine.drugInfectious diseases now
researchProduct

Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes ( REWIND ) trial…

2017

The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucagon-like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on cardiovascular outcomes. People with type 2 diabetes, aged ≥50 years, with glycated haemoglobin (HbA1c) ≤9.5%, and either a previous cardiovascular event, evidence of cardiovascular disease or ≥2 cardiovascular risk factors were randomly allocated to a weekly subcutaneous injection of either dulaglutide (1.5 mg) or placebo and followed within the ongoing Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial every 3 to 6 months. The primary cardiovascular outcome is…

medicine.medical_specialtybusiness.industryEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologymedicine.diseaseClinical trial03 medical and health sciences0302 clinical medicineEndocrinologyBlood pressureDiabetes mellitusInternal medicineHeart failureInternal MedicinemedicinePhysical therapyDulaglutideMyocardial infarctionbusinessStrokemedicine.drugDiabetes, Obesity and Metabolism
researchProduct